Literature DB >> 16099564

Application of the threshold of toxicological concern concept to pharmaceutical manufacturing operations.

David G Dolan1, Bruce D Naumann, Edward V Sargent, Andrew Maier, Michael Dourson.   

Abstract

A scientific rationale is provided for estimating acceptable daily intake values (ADIs) for compounds with limited or no toxicity information to support pharmaceutical manufacturing operations. These ADIs are based on application of the "thresholds of toxicological concern" (TTC) principle, in which levels of human exposure are estimated that pose no appreciable risk to human health. The same concept has been used by the US Food and Drug Administration (FDA) to establish "thresholds of regulation" for indirect food additives and adopted by the Joint FAO/WHO Expert Committee on Food Additives for flavoring substances. In practice, these values are used as a statement of safety and indicate when no actions need to be taken in a given exposure situation. Pharmaceutical manufacturing relies on ADIs for cleaning validation of process equipment and atypical extraneous matter investigations. To provide practical guidance for handling situations where relatively unstudied compounds with limited or no toxicity data are encountered, recommendations are provided on ADI values that correspond to three categories of compounds: (1) compounds that are likely to be carcinogenic, (2) compounds that are likely to be potent or highly toxic, and (3) compounds that are not likely to be potent, highly toxic or carcinogenic. Corresponding ADIs for these categories of materials are 1, 10, and 100 microg/day, respectively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16099564     DOI: 10.1016/j.yrtph.2005.06.010

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  5 in total

1.  Development of risk-based nanomaterial groups for occupational exposure control.

Authors:  E D Kuempel; V Castranova; C L Geraci; P A Schulte
Journal:  J Nanopart Res       Date:  2012-08-07       Impact factor: 2.253

2.  Metforminium Decavanadate (MetfDeca) Treatment Ameliorates Hippocampal Neurodegeneration and Recognition Memory in a Metabolic Syndrome Model.

Authors:  Alfonso Diaz; Guadalupe Muñoz-Arenas; Berenice Venegas; Rubén Vázquez-Roque; Gonzalo Flores; Jorge Guevara; Enrique Gonzalez-Vergara; Samuel Treviño
Journal:  Neurochem Res       Date:  2021-02-09       Impact factor: 3.996

3.  The Threshold of Toxicological Concern for prenatal developmental toxicity in rats and rabbits.

Authors:  B van Ravenzwaay; X Jiang; T Luechtefeld; T Hartung
Journal:  Regul Toxicol Pharmacol       Date:  2017-06-20       Impact factor: 3.271

4.  The Global Landscape of Occupational Exposure Limits--Implementation of Harmonization Principles to Guide Limit Selection.

Authors:  M Deveau; C-P Chen; G Johanson; D Krewski; A Maier; K J Niven; S Ripple; P A Schulte; J Silk; J H Urbanus; D M Zalk; R W Niemeier
Journal:  J Occup Environ Hyg       Date:  2015       Impact factor: 2.155

Review 5.  Considerations for setting occupational exposure limits for novel pharmaceutical modalities.

Authors:  Jessica C Graham; Jedd Hillegass; Gene Schulze
Journal:  Regul Toxicol Pharmacol       Date:  2020-11-02       Impact factor: 3.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.